RESUMO
We investigated the relationship between the functional insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene and the risk of nicotine dependence in Croatian schizophrenia patients. We also tested whether interactions between ACE-I/D polymorphism and smoking status affected the clinical psychopathology findings in patients as measured using Positive and Negative Symptom Scale (PANSS) scores. Polymerase chain reaction analysis was used to genotype 267 chronically ill schizophrenia patients (140 males/127 females). There were no significant differences in the distribution of ACE genotypes and alleles in male or female schizophrenia patients who were stratified based on their smoking status. However, there was a trend toward a difference in the ACE genotype distribution in female smokers vs. nonsmokers (χ 2 = 5.13, p = 0.077) that was due mainly to the significant overrepresentation of ACE-ID heterozygous genotypes in female smokers compared to nonsmokers (62.3 vs. 42.0%, p = 0.025). ACE-ID heterozygous females had about a twofold higher smoking risk than ACE-II and ACE-DD homozygous carriers (OR = 2.29, 95% CI 1.1-4.7, p = 0.026). We observed no contribution of the ACE genotype-smoking interaction to PANSS psychopathology. This is the first study to investigate the possible association between ACE-I/D polymorphism and nicotine dependence in schizophrenia. Our results suggest that the ACE-I/D polymorphism may be relevant in determining the risk of nicotine dependence in female patients with schizophrenia while the ACE genotype-smoking interaction does not contribute to the clinical expression of schizophrenia.
Assuntos
Peptidil Dipeptidase A/genética , Polimorfismo Genético , Esquizofrenia/complicações , Esquizofrenia/genética , Tabagismo/complicações , Tabagismo/genética , Adulto , Doença Crônica , Estudos de Coortes , Feminino , Frequência do Gene , Estudos de Associação Genética , Predisposição Genética para Doença , Técnicas de Genotipagem , Humanos , Masculino , Prevalência , Escalas de Graduação Psiquiátrica , Esquizofrenia/epidemiologia , Esquizofrenia/terapia , Fatores Sexuais , Tabagismo/epidemiologiaRESUMO
OBJECTIVE: Patients with schizophrenia are more likely to be smokers than the general population, which makes them an interesting group with which to study the etiology of nicotine dependency. We studied the prevalence of a gene variant of peroxisome proliferator-activated receptor alpha (PPARα) in schizophrenia, together with nicotine dependency, to investigate whether the PPARα-L162V polymorphism (rs1800206) influences nicotine dependency in schizophrenia. Given evidence suggesting that smoking influences the severity of schizophrenia, together with our recent data linking the PPARα-L162V polymorphism to clinical manifestations of schizophrenia (in the Croatian population), we hypothesized that interactions between the two (smoking and the PPARα-L162V polymorphism) might contribute to disease onset and scores for the Positive and Negative Syndrome Scale. To the best of our knowledge, this is the first study to investigate the possible associations between the PPARα gene and nicotine dependency. PATIENTS AND METHODS: Genotyping was performed for 267 chronically ill schizophrenia patients (males/females: 140/127) by polymerase chain reaction. RESULTS: A significant excess of PPARα-L162V genotypes and PPARα-162V alleles were detected among female smokers in comparison to female nonsmokers (18.2% vs. 2.0%, and 9.1% vs. 1.0%, p<0.01, respectively). We also revealed a significant PPARα genotype-smoking interaction that predicted positive symptom severity among male patients (F=4.43, p<0.05). These data indicated that the PPARα-L162V heterozygous genotype, depending on smoking status, might be of relevance as either protective, or a risk factor, for the severity of positive symptoms. No interaction between the PPARα-L162V polymorphism and smoking for the time of onset of schizophrenia was detected (p>0.05, respectively). CONCLUSION: We demonstrated two significant yet weak effects. The first showed an effect of the PPARα-L162V polymorphism on the risk of nicotine dependency. The second linked the PPARα genotype-smoking interaction to positive symptoms severity among schizophrenia patients; both effects manifested in a gender-specific fashion.
Assuntos
Estudos de Associação Genética , PPAR alfa/genética , Polimorfismo Genético/genética , Esquizofrenia/genética , Fumar/genética , Tabagismo/genética , Adulto , Alelos , Estudos de Coortes , Feminino , Estudos de Associação Genética/métodos , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Esquizofrenia/diagnóstico , Esquizofrenia/epidemiologia , Fumar/epidemiologia , Tabagismo/diagnóstico , Tabagismo/epidemiologiaRESUMO
Depression is an illness of modern society, which affects population of different age. Etiological factors differ, and frustration factors as a cause of depression are multiplying. Each new episode presents difficulties, both for patients and psychiatrists. Despite the increasing number of antidepressants we use in treatment, it is sometimes hard to notice an efficient antidepressant in an optimal-efficient dose. In resistant cases we apply combinations of psychopharmacs, and the choice of the same depends on the leading symptoms. We will present the case of a 67-year-old patient where a depressive episode (in the terms of a reccurent major depressive disorder) lasts for one year. During this period she was treated as outpatient and inpatient with several antidepresants in combinations with other psychopharmacotherapeutical drugs. Despite regular treatment, mental state was worsening. Clinical presentation was indicating developing of dementia (behavior, cognition outges), which we excluded through diagnostic process. Psychopharmacological combinations (antidepresants, mood stabilizators, antypschotics, anxsiolotix) were not efficant. Progression of simptoms leads to rehospitalisation. In further treatmen, we followed the principle "Less is more" which resulted with an expected and satisfactory outcome.
Assuntos
Depressão/tratamento farmacológico , Idoso , Antidepressivos/uso terapêutico , Feminino , HumanosRESUMO
Children and adolescents are being treated with antipsychotics more often than before, although the risk of adverse events in this age group still remains unclear. Because of increased use of antipsychotics in children and adolescents, their endocrine and metabolic side-effects (weight gain, obesity, and related metabolic deviations) are of particular worrying, especially within pediatric and adolescent population that appears to be at greater risk comparing with adults for antipsychotic-induced metabolic adverse events. In this work we will present the course of treatment of an adolescent girl with psychotic symptoms, within the clinical diagnosis of Organic delusional disorder, who had a considerable weight gain after one year of olanzapine treatment.
Assuntos
Antipsicóticos/efeitos adversos , Benzodiazepinas/efeitos adversos , Epilepsia/tratamento farmacológico , Transtornos Neurocognitivos/tratamento farmacológico , Aumento de Peso/efeitos dos fármacos , Adolescente , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/uso terapêutico , Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Índice de Massa Corporal , Comportamento Cooperativo , Preparações de Ação Retardada , Dibenzotiazepinas/efeitos adversos , Dibenzotiazepinas/uso terapêutico , Substituição de Medicamentos , Quimioterapia Combinada , Epilepsia/diagnóstico , Epilepsia/psicologia , Feminino , Seguimentos , Humanos , Comunicação Interdisciplinar , Lamotrigina , Transtornos Neurocognitivos/diagnóstico , Transtornos Neurocognitivos/psicologia , Olanzapina , Fumarato de Quetiapina , Triazinas/efeitos adversos , Triazinas/uso terapêuticoRESUMO
In clinical practice with adolescents we often come across with prepsychotic and psychotic disorders. When an adolescent patient has a positive hereditary burden for psychiatric illnesses in both parents, then the qualification of adolescent's mental disorder seems closer to psychotic. We must have in mind that hereditary burden is only one of many etiological factors that contribute to mental decompensations in adolescent age, that can, but don't have to be the prodrome of psychosis in the future. Whether is characterised as psychotic or not, the treatment of an adolescent in critical situation must be personalised, considering biological, social and individual factors of a patient. We believe that clinician's experience in treating psychotic adolescent patients and personalised and integrative approach to a patient is of great importance. In this article we will present the therapeutical process of a 19-year old female adolescent, with psychotic symptoms, whose both parents are psychiatric patients. A personalised and integrative approach in treatment of this patient made possible the overcome of crisis, termination of high school education and an employment. These achievements, no matter what the future can bring to this patient, create better conditions for her functioning in life.
Assuntos
Filho de Pais com Deficiência/psicologia , Conflito Familiar/psicologia , Equipe de Assistência ao Paciente , Medicina de Precisão , Transtornos Psicóticos/genética , Transtornos Psicóticos/terapia , Transtorno da Personalidade Esquizotípica/genética , Transtorno da Personalidade Esquizotípica/terapia , Criança , Terapia Combinada , Comportamento Cooperativo , Feminino , Humanos , Comunicação Interdisciplinar , Psicoterapia/métodos , Psicoterapia de Grupo/métodos , Transtornos Psicóticos/psicologia , Psicotrópicos/uso terapêutico , Fatores de Risco , Transtorno da Personalidade Esquizotípica/psicologia , Adulto JovemRESUMO
The use of antipsychotics in treatment of children and adolescents requires good knowledge of psychopathology, psychofarmacotherapy, developmental processes and family relations. It is necessary to have parental consent for the use of a medication in this age, with previous explanation of therapeutic goals, limitations and possible side effects of antipsychotics. The number of antipsychotics registered for use in children and adolescents is quite limited. The combination of clinical experience of those working with psychotic adolescents and a good collaboration with parents, creates a therapeutic space where good results in treatment can be achieved. Side effects, though rarely, can bring in question the course of treatment and disorder follow up. In this work we will present a 14-year old girl adolescent with psychotic symptoms, in which case the course of treatment and discontinuance of therapy was caused by a side effect - an oculogyric crisis.
Assuntos
Antipsicóticos/efeitos adversos , Doenças dos Gânglios da Base/induzido quimicamente , Medicamentos Genéricos/efeitos adversos , Adesão à Medicação/psicologia , Transtornos da Motilidade Ocular/induzido quimicamente , Transtornos Psicóticos/tratamento farmacológico , Risperidona/efeitos adversos , Adolescente , Antipsicóticos/uso terapêutico , Doenças dos Gânglios da Base/psicologia , Medicamentos Genéricos/uso terapêutico , Feminino , Hospitalização , Humanos , Transtornos da Motilidade Ocular/psicologia , Pacientes Desistentes do Tratamento/psicologia , Transtornos Psicóticos/psicologia , Risperidona/uso terapêutico , Recusa do Paciente ao Tratamento/psicologiaRESUMO
Background: In the ICD-11 hierarchical classification structure, posttraumatic stress disorder (PTSD) and complex PTSD (CPTSD) are separate and distinct but also 'sibling' disorders, meaning that the diagnoses follow from the parent category of traumatic stress disorders. Objective: The aim of this study was to examine the prevalence of CPTSD in treatment-seeking war veterans with PTSD more than 20 years after the exposure to cumulative war-related trauma(s). The second aim was to examine if there was an association between demographic and psychosocial variables and CPTSD or PTSD. Method: A sample of 160 male war veterans with PTSD referred to the outpatient service of the PTSD Referral Centre at the Clinical Hospital Centre (CHC) Rijeka participated in a cross-sectional study. Psychiatric comorbidity was assessed using the Mini-International Neuropsychiatric Interview (MINI) and participants completed validated self-report measures: The Life Events Checklist for DSM-5 (LEC-5), International Trauma Questionnaire (ITQ). Results: In total, 80.63% of the sample met criteria for a probable diagnosis of CPTSD. The study revealed that there was no significant difference in the length of deployment, in the intensity of the PTSD symptoms, types of trauma exposure and pharmacotherapeutic treatment between PTSD and CPTSD group. It was found that veterans with PTSD were more likely to be divorced and to participate in PTSD clubs. On the other hand, veterans with CPTSD were significantly more likely to have higher levels of functional impairment and comorbidity with general anxiety disorder (GAD) compared to the PTSD group. Conclusions: This study supports the proposition that a prolonged trauma of severe interpersonal intensity such as war is related to high rates of CPTSD among treatment-seeking veterans, years after the war. The distinction between PTSD and complex PTSD may help the selection of person-centred treatment interventions that would target specific mental health and functional problems in patients.
Antecedentes: En la estructura de clasificación jerárquica de la CIE-11, el trastorno por estrés postraumático (TEPT) y el TEPT complejo (TEPT-C) son trastornos separados y distintos, pero también "hermanos", lo que significa que los diagnósticos se derivan de la categoría principal de los trastornos por estrés traumático.Objetivo: El objetivo de este estudio fue examinar la prevalencia del TEPT-C en veteranos de guerra en busca de tratamiento con TEPT más de 20 años después de la exposición a trauma(s) acumulado(s) relacionado(s) con la guerra. El segundo objetivo fue examinar si había una asociación entre las variables demográficas y psicosociales y el TEPT-C o el TEPT.Método: Una muestra de 160 veteranos de guerra, varones con TEPT derivados al servicio ambulatorio del Centro de Referencia del TEPT en el Centro Clínico Hospitalario (CCH) Rijeka, participó en un estudio transversal. La comorbilidad psiquiátrica se evaluó utilizando la Mini-International Neuropsychiatric Interview (MINI) y los participantes completaron las medidas validadas de autoinforme: La Lista de Verificación de Eventos Vitales para el DSM-5 (LEC-5 en su sigla en inglés), Cuestionario Internacional de Trauma (ITQ en su sigla en inglés).Resultados: En total, el 80.63% de la muestra cumplió con los criterios para un diagnóstico probable de TEPT-C. El estudio reveló que no hubo diferencias significativas en la duración del despliegue, en la intensidad de los síntomas del TEPT, los tipos de exposición al trauma y el tratamiento farmacoterapéutico entre el grupo de TEPT y TEPT-C. Se descubrió que los veteranos con TEPT tenían más probabilidades de divorciarse y participar en clubes de TEPT. Por otro lado, los veteranos con TEPT-C tenían significativamente más probabilidades de tener mayores niveles de deterioro funcional y comorbilidad con Trastorno de Ansiedad General (TAG) en comparación con el grupo de TEPT.Conclusiones: Este estudio apoya la propuesta de que un trauma prolongado de intensidad interpersonal severa, como la guerra, está relacionado con altas tasas de TEPT-C entre los veteranos que buscan tratamiento, años después de la guerra. La distinción entre el TEPT y el TEPT complejo podría ayudar a la selección de intervenciones de tratamiento centradas en la persona, que apunten a problemas funcionales y de salud mental específicos en los pacientes.
RESUMO
We investigated the relationship between the rs10798059 (BanI) and rs4375 polymorphisms in the phospholipase A2 (PLA2)G4A and PLA2G6 genes and the risk of nicotine dependence in 263 Croatian patients with schizophrenia. We also examined whether interactions between these polymorphisms and smoking contributed to schizophrenia onset and Positive and Negative Syndrome Scale (PANSS) psychopathology. We found no significant differences in the distribution of PLA2G4A genotypes and alleles according to smoking status, and no effect of the PLA2G4A genotype-smoking interaction on disease onset or PANSS. The PLA2G6-TT homozygous genotype was significantly overrepresented in male smokers compared to nonsmokers (34.7% vs. 17.1%, p < 0.05). These patients had â¼2.6-fold higher risk of becoming smokers than males with heterozygous PLA2G6-CT and homozygous PLA2G6-CC genotypes. In addition, male smokers without the PLA2G6-C allele (PLA2G6-TT homozygous) experienced earlier onset than nonsmoking homozygous PLA2G6-TT males. Thus, the PLA2G6 polymorphism affected the risk of nicotine dependence in male patients and the PLA2G6 genotype-smoking interaction was linked to the age of disease onset.
Assuntos
Fosfolipases A2 do Grupo VI/genética , Polimorfismo de Nucleotídeo Único , Esquizofrenia/genética , Tabagismo/epidemiologia , Adulto , Idade de Início , Croácia , Feminino , Estudos de Associação Genética , Fosfolipases A2 do Grupo IV/genética , Humanos , Masculino , Pessoa de Meia-Idade , Caracteres Sexuais , Tabagismo/genéticaRESUMO
OBJECTIVE: The objective of the research was to determine whether the administration of antidepressants, concurrently with antihypertensive therapy, leads to the better regulation of blood pressure in patients with hypertension and increased depressiveness. METHODS: Research was conducted in two outpatient family clinics in Rijeka, Croatia, on 452 patients with arterial hypertension who had not been diagnosed with depression prior to the study. The diagnosis of hypertension was made in accordance with the European Society of Hypertension and the European Society of Cardiology Guidelines for the Management of Arterial Hypertension. Using the Beck Depression Inventory and the ICD-10 criteria for depression, a group of depressed hypertensive patients (N = 134) was selected. Out of a total of 134 selected patients, 73 patients (N = 73) were receiving antidepressants together with antihypertensives for 24 weeks. They formed the experimental group. The rest of the patients (N = 61) continued to receive only antihypertensives and they formed the control group. RESULTS: After the end of the 24-week therapy, the experimental group of patients had significantly lower levels of both systolic and diastolic blood pressure (Z = 7.42; P < 0.001; and Z = 7.36; P < 0.001). The control group saw no significant difference between the level of blood pressure (both systolic and diastolic) prior to and after this period. CONCLUSION: The application of antidepressant therapy in patients with hypertension who are also depressed may be associated with the better control of blood pressure, which reduces the risk of cardiovascular disease in addition to alleviating depressive symptoms.